Analytical Data
-
Gene name
HEMK2
- Application
-
Alternative Names
M.HsaHemK2P N(6)-adenine-specific DNA methyltransferase 1
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y5N5
-
Expression Region
1-186aa
-
Molecular Weight
46.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HEMK2, or Hematopoietic-specific protein 2, is a member of the Hematopoietic and endothelial-specific protein family, playing a crucial role in hematopoiesis and endothelial functions. Research into HEMK2 recombinant proteins has gained momentum due to its potential implications in understanding blood cell development and vascular biology. The study of this protein is particularly significant as it may provide insights into various hematological disorders and cardiovascular diseases. Recombinant expression techniques allow for the production of HEMK2 in controlled laboratory settings, facilitating detailed investigations into its structure, function, and interactions with other molecular pathways. Advances in this area could lead to the identification of novel therapeutic targets and biomolecular markers for diseases associated with abnormal hematopoietic and endothelial function. Additionally, HEMK2's involvement in cellular signaling processes positions it as a critical player in the development of targeted treatments aimed at modulating these pathways. Overall, the exploration of HEMK2 recombinant protein not only enhances our fundamental understanding of its biological roles but also holds promise for innovative approaches in clinical research and therapeutic development.
